Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Buy rating

ME Staff
-
0

Analyst Ratings For Aridis Pharmaceuticals Inc (NASDAQ:ARDS)

Today, Maxim Group initiated coverage on Aridis Pharmaceuticals Inc (NASDAQ:ARDS) with a Buy.

There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Aridis Pharmaceuticals Inc (NASDAQ:ARDS) is Buy with a consensus target price of $29.3333 per share, a potential 135.61% upside.

Some recent analyst ratings include

  • 10/2/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Buy rating
  • 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Outperform rating and $40.00 price target
  • 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Outperform rating
  • 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Buy rating and $23.00 price target
  • 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Overweight rating


    About Aridis Pharmaceuticals Inc (NASDAQ:ARDS)
    Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals Inc. was founded in 2003 and is headquartered in San Jose, California.

    Recent Trading Activity for Aridis Pharmaceuticals Inc (NASDAQ:ARDS)
    Shares of Aridis Pharmaceuticals Inc closed the previous trading session at 12,44 −0,55 4,23 % with 13.06 shares trading hands.